**INTRODUCTION**

Congestive heart failure (CHF) is a major public health problem. Nearly 5 million Americans are afflicted with CHF and about 550,000 new cases are diagnosed each year (1). CHF is a pathophysiological condition in which the heart is unable to pump enough blood to meet the metabolic needs of the body. It is the endpoint for several cardiovascular diseases including coronary artery disease, myocardial infarction, hypertension, cardiomyopathy, congenital heart defects, myocarditis, and valvular heart disease resulting from rheumatic fever or endocarditis. Regardless of the etiology, compensatory and adaptive changes occur in the heart to preserve cardiac output. Some of these changes are mediated by enhanced sympathetic nervous system activity (2). Increased catecholamine outflow from this system induces sustained elevated activation of the $\beta$-adrenergic receptors ($\beta$-ARs), which results in abnormalities in the $\beta$-AR signaling system that may ultimately lead to the pathogenesis of CHF (3).

In this review, I will discuss (i) $\beta$-AR subtypes in the heart; (ii) the functional role of $\beta$-AR signaling in CHF; and (iii) the recent studies in genetically engineered mice to elucidate the functional effects and therapeutic potential of critical genes in the cardiac $\beta$-AR signal transduction pathways.

**$\beta$-ARs IN THE HEART**

The $\beta$-ARs belong to the superfamily of membrane proteins known as G-protein-coupled receptors (GPCRs) (4). GPCRs are characterized by a conserved core structure with extracellular amino terminus, intracellular carboxyl terminus and seven transmembrane $\alpha$-helices, which are connected by three extracellular and three intracellular loops. They transduce extracellular signals from endogenous hormones and neurotransmitters, ambient physical and chemical stimuli, as well as exogenous therapeutic agents. GPCRs are involved in regulation of a vast array of physiological processes including sensory perception, cell growth, metabolism and hormonal homeostasis.

The transmembrane signaling by GPCRs is initiated by the binding of ligands such as hormones or neurotransmitters (Figure 1). Ligand binding induces a conformational change in GPCRs that causes coupling with heterotrimeric G-proteins (5). G-proteins consists of $\alpha$, $\beta$, and $\gamma$ subunits and GPCR coupling leads to the exchange of G-protein-bound GDP for GTP and the dissociation of the G-protein into active $G_{\alpha}$ and G$\beta$ subunits to mediate downstream signaling. Based on their amino acid sequences and function, $G_{\alpha}$ subunits are grouped into four subfamilies - $G_{\alpha}S$, $G_{\alpha}I$, $G_{\alpha}Q$ and $G_{\alpha}12$ (6). Subunits of the diverse G-proteins differentiate the cellular signal by modulating the activity of various effector molecules such as adenylyl cyclase (AC) or phospholipase C-$\beta$. These effector molecules regulate the concentrations of second messengers in the cell, activating a number of different downstream signaling molecules.

There are four subtypes of $\beta$-ARs-$\beta_1$-AR, $\beta_2$-AR, $\beta_3$-AR and the $\beta_4$-AR (6). The $\beta_1$-AR is found primarily in the heart and comprises 75-80% of the $\beta$-ARs found in CHF; and (iii) the recent studies in genetically engineered mice to elucidate the functional effects and therapeutic potential of critical genes in the cardiac $\beta$-AR signal transduction pathways.

*To whom correspondence should be addressed: Aasakiran Madamanchi, 1307 Crimson Creek DR., Durham, NC, 27713, USA Tel: 919-451-9073
(cAMP); heightened cAMP levels activate cAMP-dependent protein kinase A (PKA). Activated PKA then phosphorylates troponin I, the L-type Ca\(^{2+}\) channel and phospholamban (PLB), resulting in greater contractility (8). In addition to Gs, the \(\beta_2\)-AR couples to pertussis toxin - sensitive G inhibitory (Gi) protein. G\(_i\) coupling releases the activated G\(_i\)α subunit, which inhibits AC activity, and the G\(_{i\beta\gamma}\) subunit, which causes downstream activation of the mitogen-activated protein kinases (MAPK). G\(_{i\alpha}\) coupling also activates the cytosolic effector molecule phospholipase A2 (cPLA2), which causes cAMP-independent enhancement of calcium signaling and cardiac contraction. Recent studies indicate that \(\beta_2\)-AR-cPLA2 pathway substitutes for a deficient \(\beta_1\)-AR-Gs-cAMP pathway; decreased \(\beta_1\)-AR-AC coupling promotes the \(\beta_2\)-AR-cPLA2 pathway, whereas efficient \(\beta_1\)-AR-AC coupling suppresses it by the activity of PKA (9). The effect of cardiac \(\beta_2\)-AR activation varies depending on the species, and the developmental or pathophysiological state of the heart (9). The ability of \(\beta\)-ARs to couple with different G-proteins allows for the receptors to activate multiple signaling pathways and initiate diverse cellular responses.

The \(\beta\)-AR signaling system, like all GPCR systems, has a number of post-agonist stimulation regulatory mechanisms that serve to prevent overstimulation (10). These processes, together known as receptor desensitization, act as a negative feedback to the \(\beta\)-AR signal, under conditions of extended agonist stimulation, by repressing the intensity of \(\beta\)-AR signaling and decreasing the total number of receptors in the cell. The first of these processes is the deactivation of trimeric G-proteins. Soon after the dissociation of the coupled G-protein into active G\(_{i\gamma}\) and G\(_{i\beta\gamma}\) subunits, conformational changes occur that cause re-formation of the inactive G-protein. The rapid termination of the G-protein signal maintains the dose-dependent nature of \(\beta\)-AR signal propagation and resets the protein for future signaling. Although apparently contradictory, \(\beta\)-AR desensitization (discussed later) much like chronic receptor stimulation, contributes to the pathogenesis of CHF (3).

Continuous catecholamine stimulation overwhelms the short-term active/inactive cycling of the G-protein signal and triggers further negative feedback regulation of GPCR activity. Activation-dependent regulation of receptors, also known as homologous desensitization, proceeds within minutes of agonist stimulation (11). Homologous desensitization begins when the G\(_{i\beta\gamma}\) subunit of the activated G-protein binds with the active form of a G-protein-coupled receptor kinase (GRK). GRK2, also known as \(\beta\)-AR kinase 1 (\(\beta\)ARK1), is translocated to the stimulated receptor after binding with the activated G\(_{i\beta\gamma}\) subunit, where it phosphorylates the agonist-occupied \(\beta\)-AR (8). \(\beta\)ARK1 is the most prominent cardiac GRK; GRK3 and GRK5, which are also capable of phosphorylating \(\beta\)-ARs, are present in cardiac myocytes in minimal levels. Phosphorylation of the receptor occurs at the C-terminus of the receptor.
protein and targets it for arrestin-induced functional uncoupling from the G-protein. An alternate internalization pathway involves phosphorylation of the receptor protein through the secondary action of a downstream signaling product of β-AR activation. This process, known as heterologous desensitization, is initiated when the second messenger-regulated kinase PKA phosphorylates the β-AR (12). As opposed to homologous desensitization, heterologous desensitization indiscriminately phosphorylates both stimulated and unstimulated receptors. In both cases, receptor phosphorylation allows for β-arrestin to bind and interfere with future association with G-proteins, functionally uncoupling the receptor (13). Binding to β-arrestin increases the receptor’s affinity for adaptor protein (AP)-2 and clathrin (14). Internalization of receptors via clathrin-coated vesicles follows rapidly, within minutes of stimulation (15).

Following internalization, receptors are transported to endosomes. At the endosomes, the receptors can be recycled back to the plasma membrane where they return to a complete functioning state (14). In response to persistent receptor stimulation, the internalized receptor can instead be degraded in the liposome. This process, known as down-regulation, lowers the total number of receptors in the cell to relieve chronic overstimulation. Down-regulation is initiated within hours to days after consistent receptor internalization.

**β-AR SIGNALING IN HEART FAILURE**

As the major component of the interface between the sympathetic nervous system and the cardiovascular system, the β-AR signaling pathway emerges as a key actor during the progression of heart failure. Prominent irregularities in β-AR signaling changes include a reduction of the β1-AR levels of up to 50% (interestingly β2-AR levels remain constant), a sharp increase (up to 200%) of GαI levels, and significantly elevated βARK1 activity (8). All of these adjustments reflect severely diminished β-AR signaling, likely the result of sustained, elevated catecholamine levels.

Cardiac hypertrophy often directly precedes the onset of CHF. Excessive stress activates a complex network of interacting pathways that initiate myocardial hypertrophy to preserve cardiac function. Conventional wisdom held that cardiac hypertrophy is an adaptive process that improves ventricular function in the face of a growing workload. However, as the cardiac efficiency of the hypertrophied heart further diminishes, the sympathetic nervous system is increasingly activated in an attempt to maintain cardiac output and systemic blood pressure (16). Furthermore, many studies indicate that sustained cardiac hypertrophy is closely associated with reduced contractility and an increased risk of heart failure.
failure (17). Also, significant desensitization of β-ARs and other β-AR signaling irregularities are shared characteristics in the development of cardiac hypertrophy and the progression of heart failure. Transgenic mice that lack a hypertrophic response mechanism suffer less cardiac dysfunction than normal mice when facing long-term mechanical stress (18). In light of this evidence, a new paradigm has emerged in which it is argued that the signaling pathways stimulated during the hypertrophic process may actually play a greater role in the pathogenesis of heart failure than the original stress on the heart.

According to this model, heightened stimulation by the sympathetic nervous system elicits a hypertrophic response in the heart that is initially beneficial but becomes maladaptive when sustained. The hypertrophic response causes the activation of a number of signaling pathways, at a time when consistently elevated catecholamine levels are already overstimulating the β-AR signaling pathways. Sustained activation of the β-AR system combined with biochemical changes produced by hypertrophic processes strongly activate desensitization and down-regulation pathways, which ultimately lead to diminished β-AR function and loss of contractility.

LESSONS FROM TRANSGENIC MOUSE MODELS

Over the last decade and a half, cardiovascular research has been revolutionized through the use of genetically engineered mouse models. Mouse lines have been developed to model every aspect of cardiac pathology. Furthermore, the use of murine α-myosin heavy chain (αMyHC) gene promoter in ventricular myocytes has enabled cardiac-specific gene expression. The αMyHC promoter, which is inactive until around birth, avoids developmental complications arising from the specific transgene overexpression (15). The ability to genetically manipulate molecular components of the β-AR signaling system in murine heart failure models provides a powerful experimental system for uncovering potential roles of various elements of this system in the pathophysiology of cardiac failure.

β₁-AR

The β₁-AR has been studied in both gain and loss of expression studies. β₁-AR knockout mice were largely embryonically lethal, while the surviving mice showed no response to catecholamine stimulation despite the presence of β₂-ARs (19). Cardiomyocyte-targeted overexpression of the β₁-AR using the αMyHC promoter generated mice with 5 to 15-fold overexpression of β₁-ARs. The β₁-AR overexpressing mice developed dilated cardiomyopathy and heart failure at young age, which is similar to the pathology caused by chronic catecholamine overstimulation (20). This data reinforced the view that increased β-AR signaling, as happens in chronic receptor stimulation, is ultimately detrimental to cardiac function.

β₂-AR

Experiments using transgenic mouse models have made it clear that β₁-AR and β₂-AR are not identical signaling molecules. In contrast to β₁-AR knockouts, the β₂-AR knockout mice do not suffer from developmental defects and show no significant differences in cardiovascular phenotype when compared with wild-type mice (21). The β₂-AR knockout mice also differ from β₁-AR knockouts in that they show typical response to catecholamine stimulation. This indicates that the β₁-AR is the signaling conduit for the catecholamine-induced changes in cardiac contractility.

Mice with cardiac-specific overexpression of β₂-ARs displayed enhanced basal contractility and cardiac function with minimal pathology (22). Adenoviral-mediated gene transfer of β₂-AR to myocytes from a rabbit heart failure model rescued β-AR signaling (23). Crossing transgenic mice overexpressing moderate amounts (30-fold above wild-type levels) of cardiac β₂-AR with transgenic mice overexpressing Ga₉₉ improved cardiac function and hypertrophy in the Ga₉₉ overexpression heart failure model (24). These results are encouraging for the prospective use of β₂-AR overexpression as a therapeutic approach. However, conflicting data clouded the issue as β₂-AR overexpression has failed to rescue other heart failure models (25) and has proven deleterious in the face of pressure overload (26). More information about appropriate levels of β₂-AR expression levels is needed to clarify the potential therapeutic value of β₂-AR gene transfer.

βARK1

The prevalence of βARK1 activity in the progression of maladaptive hypertrophy and cardiovascular disease has made it an object of extensive research. The role of βARK1 was investigated by studying the contrast between hearts of transgenic mice overexpressing βARK1 and those expressing a peptide inhibitor of βARK (βARKct). βARKct, a peptide expressing the terminal 194 amino acids of βARK1, contains the Gβγ-binding domain and competes with endogenous βARK1 for Gβγ subunits necessary for βARK1 activity (27). Overexpression of βARK1 in transgenic mice showed a diminished β-AR response to catecholamine stimulation. This mirrors the augmented βARK1 activity observed in human heart failure. In stark contrast, the βARKct mice had enhanced cardiac function under normal conditions and an augmented
response to catecholamine stimulation (28). While homozygous βARK1+/− mice were embryonic lethal, heterozygous βARK1+/− mice had a cardiac phenotype of enhanced contractility similar to the βARKct transgenic animals (29, 30).

To determine the significance of increased βARK activity in the progression of heart failure, a number of studies were conducted involving the overexpression of βARKct in mice from various existing heart failure models. Remarkably, in each case, it was shown that cardiac overexpression of βARKct leads to prevention of progressive deterioration in cardiac function, prevention of hypertrophy, improved exercise tolerance, and correction of β-AR dysfunction (31). Furthermore, adenoviral delivery of βARKct to larger animal models of heart failure has shown therapeutic effects (32). Taken together, these studies indicate that inhibition of βARK1 activity can preserve β-AR signaling and lead to an improved response to catecholamine stimulation. This suggests that inhibition of βARK1 activity via introduction of βARKct or other small molecule inhibitors is a viable therapeutic approach for disease states characterized by increased βARK1 activity.

It is important to note that the effects of βARK1 inhibition may not be completely relegated to the β-AR system as βARK1 is involved in a number of non-β-AR signaling pathways (33). Furthermore, the demonstrated effectiveness of βARKct expression may not be entirely attributable to βARK1 inhibition. βARKct functions by binding to and interfering with activated Gβγ subunits, so it is very possible that inhibition of alternative Gβγ pathways contributes to part of the βARKct effect. In fact, recent evidence has shown that another Gβγ inhibitor, a N-terminally truncated phosducin, which acts independently of β1-AR activity, replicates βARKct’s protective effects (34).

PI3K

Recently, phosphoinositide 3-kinase (PI3K) has begun to garner interest because of its role at the intersection of the hypertrophic and β-AR signaling processes. PI3K, which belongs to a conserved family of lipid kinases that are involved in the regulation of a variety of cellular functions including cell growth, survival, signal transduction and apoptosis, is activated in cardiac myocytes during the hypertrophic response (35). PI3K activity is also closely associated with attenuation of β-AR function resulting in decreased contractility (36, 37). Recent studies demonstrated that βARK1 interacts with the phosphoinositide kinase (PIK domain) of PI3K to form a cytosolic complex and facilitates agonist-mediated PI3K translocation to the plasma membrane (38). PI3K, via its lipid kinase activity, catalyzes the production of D-3 phosphoinositides, which recruit adaptor proteins essential to receptor internalization.

Overexpression of the PIK domain, which competitively displaces endogenous PI3K and prevents βARK-PI3K translocation to the membrane, significantly decreased agonist-stimulated β-AR internalization. Recently, we demonstrated that internalization of the receptor also requires the protein kinase activity of PI3K involving tropomysin phosphorylation (39). Furthermore, overexpression of PI3Kγ1, a catalytically inactive mutant, inhibited agonist-induced β-AR internalization and rescued β-AR function in calsequestrin overexpressing (CSQ) mice, a common heart failure model (40). Restoration of β-AR signaling via PI3Kγ overexpression resulted in significant improvement in cardiac function and survival, which indicates that inhibition of membrane-targeted PI3K represents a novel therapeutic approach to ameliorate cardiac dysfunction.

CONCLUSIONS AND NEW DIRECTIONS

In recent years, great progress has been made towards understanding the β-AR system and its role in heart disease. Increasingly, researchers are viewing the myocardial hypertrophic response and concurrent β-AR desensitization as maladaptive responses. However, this evolving notion is counterintuitive to the successful use of β-blockers which favor a reduction of β-AR stimulation to preserve cardiac function. Understanding the differences between β1-AR and β2-AR signaling may explain the apparent effectiveness of these β-antagonists in restoring β-AR levels and cardiac function in the failing heart. It is possible that β-blockers function by inhibiting sustained β1-AR activity and the associated hypertrophic, pro-apoptotic, pro-necrotic effects (24). Another possibility is that β-blockers act to re-sensitize the β-AR system, reversing the abnormalities in β-AR signaling that result from prolonged catecholamine stimulation.

Studies using genetically altered mice have identified Gβγ and PI3K as particularly promising targets for therapeutic intervention. Further investigation of the secondary signaling pathways these molecules are involved in, is needed to fully understand how best to target these molecules for the treatment of CHF. Potential approaches include the use of gene therapy (with βARKct or PI3Kγ1) or the development of pharmaceutical inhibitors for heart-specific βARK1 or PI3K activity.

ACKNOWLEDGEMENT

I am grateful to Drs. Sathyamangla Naga Prasad and Howard Rockman at Duke University and Dr. Aleksandr Vendrov at University of North Carolina, Chapel Hill, for their encouragement and critical reading of the manuscript.
REFERENCES

1. Heart and stroke statistical update. Dallas, Tx: American Heart Association; 2001.
2. Leimbach WN, Wallin G, Victor RG et al. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986; 93: 720-729.
3. Koch WJ. Genetic and phenotypic targeting of beta-adrenergic signaling in heart failure. Molecular and Cellular Biochemistry 2004; 263: 5-9.
4. Vassilatis DK, Hohmann JG, Zeng H, et al. The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci U S A 2003; 100: 4903-8.
5. Wess J. G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J 1997; 11:346-354.
6. Xiao R. Beta-adrenergic signaling in the heart: dual coupling of the beta2-adrenergic receptor to G(s) and G(i) proteins. Sci STKE 2001;RE15.
7. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathetic drugs, and adrenergic receptor antagonists. In: Hardman J, Limbird L, editors. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996:199-248.
8. Freedman NJ, Lefkowitz RJ. Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest 2004; 113: 1379-82.
9. Pavoine C, Defer N. The cardiac beta2-adrenergic: signaling a new role for the cPLA2. Cell Signal 2005; 17:141-152.
10. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacology Rev 2001; 53:1-24.
11. Barak LS, Arabic K, Fang X, et al. Real-time visualization of the cellular redistribution of G protein-coupled receptor kinase 2 and beta-arrestin 2 during homologous desensitization of the substance P receptor. J Biol Chem 1999; 274:7565-7569.
12. Freedman NJ, Lefkowitz RJ. Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest 2004; 113: 1379-82.
13. Perry SJ, Lefkowitz RJ. Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol 2002; 12:130-8.
14. Claign A, Laporte SA, Caron MG, et al. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol 2002; 66:61-79.
15. Zhang J, Ferguson SS, Barak LS, et al. Dynamin and beta-arrestin reveal distinct mechanisms for G protein-coupled receptor internalization. J Biol Chem 1996; 271:18302-5.
16. Esler M, Kaye D, Lambert G et al. Adrenergic nervous system in heart failure. Am J Cardiol 1997; 80:7L-14L.
17. Katz AM. Evolving concepts of heart failure: cooling furnace, malfunctioning pump, enlarging muscle. Part II: Hypertrophy and dilatation of the failing heart. J Card Fail 1998; 4:67-81.
18. Esposito G, Rapacciulo A, Naga Prasad SV, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 2002; 105: 85-92.
19. Rohrer DK, Desai KH, Jasper JR et al. Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects. Proc Natl Acad Sci U S A 1996; 93:7375-80.
20. Engelhardt S, Hein L, Wissmann F, et al. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 1996; 96: 7059-64.
21. Chruscienski AJ, Rohrer DK, Schauble E, et al. Targeted disruption of the beta2 adrenergic receptor gene. J Biol Chem 1999; 274:16694-16700.
22. Milano CA, Allen LF, Rockman HA, et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science 1994; 264: 582-6.
23. Akhter SA, Skaer CA, Kypson AP, et al. Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci U S A 1997; 94: 12110-5.
24. Dorn GW 2nd, Tepe NM, Lorenz JN, et al. Low-and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphq-overexpressing mice. Proc Natl Acad Sci U S A 1999; 96: 6400-5.
25. Freeman K, Lerman I, Kranias EG, et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest 2001; 107: 967-74.
26. Du XJ, Autelitano DJ, Dilley RJ, et al. Beta(2)-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 2000; 101:71-77.
27. Koch WJ, Inglese J, Stone WC, et al. The binding site for the beta gamma subunits of heterotrimeric G proteins on the beta-adrenergic receptor kinase. J Biol Chem 1993; 268:8256-60.
28. Koch WJ, Rockman HA, Samama P, et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 1995; 268:1350-3.
29. Jaber M, Koch WJ, Rockman H, et al. Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function. Proc Natl Acad Sci U S A 1996; 93:12974-9.
30. Rockman HA, Choi DJ, Akhter SA, et al. Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice. J Biol Chem 1998; 273:18180-4.
31. Brisot MR. Why does the myocardium fail? Insights from basic science. Lancet 1998; 352 Suppl 1:18-14.
32. Shah AS, White DC, Emani S, et al. In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 2001; 103: 1311-6.
33. Eckhart AD, Duncan SJ, Penn RB, et al. Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. Circ Res 2000; 86:43-50.
34. Li Z, Laugwitz KL, Pinkernell K, et al. Effects of two Gbetagamma-binding proteins—N-terminally truncated phosphducin and beta-adrenergic receptor kinase C terminus (betaARKct)—in heart failure. Gene Ther 2003; 10: 1354-61.
35. Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 1999; 274:3437-50.
36. Shioi T, Kang PM, Douglas PS, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 2000; 19:2537-48.
37. Crackower MA, Oudit GY, Kozieradzki I, et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002; 110:737-749.
38. Naga Prasad SV, Laporte SA, Chamberlain D, et al. Phosphoinositide 3-kinase regulates beta2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/beta-arrestin complex. J Cell Biol 2002; 158:563-575.
39. Naga Prasad SV, Jayatilleke A, Madamanchi A, et al. Protein kinase activity of phosphoinositide 3-kinase regulates beta-adrenergic receptor endocytosis. Nat Cell Biol 2005; 7:785-796.
40. Perrino C, Naga Prasad SV, Patel M, et al. Targeted inhibition of beta-adrenergic receptor kinase 1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. J Am Coll Cardiol 2005; 45:1862-70.